Tenax Buys PH Precision Med, Plans Trial for Oral Imatinib

Tenax Buys PH Precision Med, Plans Trial for Oral Imatinib

283430

Tenax Buys PH Precision Med, Plans Trial for Oral Imatinib

Tenax Therapeutics has acquired PH Precision Med (PHPM), a private biotech focused on developing imatinib as a treatment for pulmonary arterial hypertension (PAH). “The acquisition of PHPM immediately expands Tenax’s pipeline to include a second de-risked Phase 3 ready candidate with the potential to be the first disease modifying treatment of pulmonary arterial hypertension,” Anthony DiTonno, Tenax’s CEO, said in a press release. Imatinib is marketed as Gleevec and used to treat certain types of…

You must be logged in to read/download the full post.